BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Nov 19, 2007
 |  BioCentury  |  Product Development

Hoping to be the exception

If EMEA approves Introgen Therapeutics Inc.'s MAA for Advexin to treat Li-Fraumeni Syndrome cancers, it would be the first gene therapy to be approved outside of China. The question is how little data the agency will accept for an Orphan disorder for which there are no approved drugs and in which the company conducted no trials.

LFS is an autosomal dominant hereditary disorder involving mutations in the p53 tumor suppressor gene, making carriers highly susceptible to developing a variety of cancers at an early age. Introgen (INGN, Austin, Texas) estimates that LFS affects 800-1,000 families in the U.S. and Europe.

Advexin (INGN 201) is an adenovirus p53 gene therapy that is injected intratumorally. According to Max Talbott, SVP of worldwide commercial development, Advexin "works for a short time and basically serves as a p53 factory inside human cells by making the tumor suppressor that is in an aberrant or...

Read the full 736 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >